Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05479994 | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | PHASE2 | ACTIVE NOT_RECRUITING | 100 | — | — | Oct 25, 2022 | Aug 25, 2027 | Mar 4, 2026 | 50 | China |
Defined as the proportion of participants who achieved a complete response (CR), complete remission with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) per the 2018 iwCLL guidelines for participants with chronic lymphocytic leukemia (CLL) or Defined as the proportion of participants who achieved PR or better per the Lugano Classification for partiticpants with small lymphocytic lymphoma (SLL)
| Arm | Type | Description |
|---|---|---|
| Treatment Arm | EXPERIMENTAL | Participants will receive BGB-11417 orally until disease progression, intolerable toxicity, or other scenarios specified in the protocol |
| Name | Type | Description |
|---|---|---|
| BGB-11417 | DRUG | Administered orally |
Key Inclusion Criteria 1. Participants with a histologically confirmed diagnosis of CLL/SLL based on the International Workshop on CLL (iwCLL) criteria: 1. Treatment intolerance or failure during or after treatment with chemoimmunotherapy (CIT) and BTK inhibitors (BTKi) or 2. Treatment intol...